Abbreviation glossary

Singapore's national health-technology assessment agency within the Ministry of Health.

Advises Zorginstituut on societal and package-management considerations for consequential cases.

A harmonized dossier format used for medicine registration in ASEAN markets.

Abu Dhabi committee supporting health-technology assessment and coverage governance.

Administers and transfers health-system resources in Colombia.

The approved ex-manufacturer price used as a core PBS pricing reference.

Spain's national medicines regulator.

Italy's national medicines, pricing and reimbursement authority.

The Portuguese term for a medicine marketing authorisation.

The publicly recorded Dutch pharmacy purchase price, which is not necessarily the payer's or hospital's net cost.

Germany's framework for early benefit assessment and reimbursement negotiation.

Argentina's medicines and health-products regulator.

France's medicines safety and regulatory agency.

Brazil's medicines and health-products regulator.

Poland's health-technology assessment agency.

A context-dependent abbreviation. In regional labels it means Asia-Pacific; in Brazil's SUS pathway it means the authorization, information and billing instrument for high-complexity or high-cost outpatient procedures, including oncology.

Swiss comparison of the same medicine's price in specified reference countries.

The legal register of therapeutic goods that can be supplied in Australia.

Regional organization that supports regulatory harmonization among Southeast Asian member states.

French rating of added clinical benefit versus comparators.

Swiss federal authority that decides ambulatory inclusion and price in the Spezialitätenliste.

Austrian federal authority for medicine and health-product regulatory functions.

The Vietnamese term for health insurance and its medicine-benefit rules.

Estimates how adopting a medicine changes payer spending for a defined population and time horizon.

Administers Indonesia's national JKN health-insurance programme.

Indonesia's authority for medicine and food regulation.

Closed-network catastrophic-cost protection attached to Chilean ISAPRE plans.

Conducts health-technology assessment for participating Canadian public plans.

India's central medicines regulator.

Economic comparison of additional cost and health benefit.

Chile's public medicine procurement, intermediation and logistics organisation; it does not decide coverage.

Negotiates medicine prices in France.

Advises on national reimbursement prices and insurance policy.

Decides national medicine financing and prices in Spain.

The quality and manufacturing section of a pharmaceutical development and registration package.

Sets and regulates maximum medicine prices in Brazil.

A context-dependent abbreviation: the US federal administrator of Medicare and Medicaid, or South Africa's regulator of medical schemes.

Colombian national commission responsible for medicine and medical-device price policy.

Mexico's health-products regulator.

Supports national health-technology evaluation in Argentina.

Assesses technologies for incorporation into Brazil's public health system.

The Philippine FDA certificate authorising a specified product for marketing.

HSE unit coordinating medicine pricing, reimbursement and commercial negotiation.

Assesses medicines for reimbursement in Belgium.

National body involved in health-benefit and formulary decisions.

Kazakhstan's compulsory social health-insurance package with its own eligibility and funding boundaries.

The internationally harmonized modular format for medicine registration dossiers.

Identifier for the exact registered medicine presentation in Colombia.

Advises Singapore's Ministry of Health on public funding for drugs, vaccines and gene therapies.

Vietnam's national medicines regulatory authority.

Makes product-registration decisions in Malaysia.

Norwegian authority for medicines regulation, maximum prices and public-financing assessments.

Pakistan's federal authority for medicine registration, quality and regulated pricing.

A provider or network designated by a South African medical scheme for covered care.

Regional union operating common rules for medicine registration alongside national transition arrangements.

Advisory commission supporting BAG medicine reimbursement assessment.

Grants centralized EU marketing authorizations following EMA review.

Egypt's authority for medicine registration, regulation and official pricing.

Federal UAE authority responsible for medicine regulation and related product controls.

Austria's outpatient reimbursement code with red, yellow and green access categories.

Coordinates scientific evaluation of medicines in the European Union.

Colombian insurer/health-plan entity responsible for member access, network direction and care delivery.

Political and economic union whose centralized medicines pathway applies across participating member states.

Belgium's medicines regulator.

United States medicines regulator.

Chile's public health-insurance fund.

Germany's highest decision-making body for statutory healthcare benefits.

Accredits and regulates providers eligible to contract within Egypt's universal insurance system.

Condition-specific Chilean guarantees for access, timeliness, financial protection and quality.

Represents statutory health insurers in national reimbursement negotiation.

Kazakhstan's state-guaranteed package of publicly funded health services and medicines within defined scope.

The Dutch statutory outpatient medicines reimbursement system, including Lists 1A, 1B and reimbursement conditions in List 2.

France's independent health-technology assessment authority.

Committee assessing medicines for the Austrian EKO process.

Administers specified national health reimbursements and patient/provider claims.

Evidence discipline examining costs, outcomes, value and real-world impact of healthcare interventions.

Legacy Egyptian public insurance organisation that remains relevant alongside phased UHIS rollout.

Assesses reimbursement suitability and reviews healthcare claims in South Korea.

Supports health-technology and economic evaluation for policy decisions in Thailand.

Ireland's national medicines and health-products regulator.

Singapore's regulator for therapeutic products.

Ireland's public health-service organisation and medicine funding decision maker.

A structured assessment of clinical, economic and wider system value.

Philippine body making HTA recommendations to public health decision makers.

India's public health-technology assessment program.

Incremental cost divided by incremental health outcome.

Develops harmonized technical requirements for pharmaceutical product registration.

Colombian institute performing health-technology and therapeutic-value assessment.

Major public social-insurance provider in Mexico.

Case-based hospital payment groups used in Indonesia's JKN system.

Belgium's federal health and disability insurance institution, known by its French and Dutch abbreviations.

Quebec's health-technology assessment body.

Portuguese authority responsible for medicine regulation, HTA, pricing and reimbursement.

Colombia's medicine and food regulatory authority.

A Colombian healthcare provider institution within an EPS network.

Independent scientific institute supporting benefit assessment in Germany.

A private health-insurance institution in Chile.

Chile's public-health institute and pharmaceutical regulator.

Public insurer for federal government workers in Mexico.

Indonesia's national social health-insurance programme.

National formulary evidence framework; inclusion is distinct from a funded benefit-list entry or procurement award.

Norwegian hospital-medicine procurement collaboration operated through Sykehusinnkjøp.

Chilean universal financial-protection system for treatments expressly included by high-cost decree.

Subsidy route for selected clinically necessary medicines outside the Standard Drug List.

An Irish protocol defining patient, prescriber, approval and monitoring conditions for selected medicines.

Evaluates medicines for quality, safety and efficacy in New Zealand.

South Korea's medicines regulator.

Japanese ministry responsible for approval, insurance listing and health policy.

United Kingdom medicines regulator.

Platform for prescribing and tracing specified non-UPC and other health technologies; it is not a payer or formulary.

HSE programme supporting evidence-based, safe and cost-effective medicine use.

A national health ministry; its exact remit differs by market.

Public-sector formulary for medicines used in Malaysia's Ministry of Health facilities.

Publishes final reimbursement and health-policy decisions in South Korea.

A context-dependent abbreviation: a regulated retail-price ceiling in some markets, or an EU regulatory reliance procedure.

Kazakhstan's expert organization for medicine quality, safety and efficacy assessment.

Performs Rapid Reviews and full pharmacoeconomic assessments for the Irish HSE.

A formal application seeking authorization to market a new medicine.

A national reference list of priority essential medicines; local funding and procurement remain separate.

Selects and reviews medicines for South African public-sector STGs and EMLs.

Japan's universal national health-insurance reimbursement system.

South Korea's single national insurer and medicine price negotiator.

Publicly funded healthcare system in the United Kingdom.

China's national medical-insurance and reimbursement authority.

Administers Thailand's Universal Coverage Scheme and related purchasing and access policies.

Appraises clinical and cost effectiveness for England.

Core pharmaceutical benefit list used across Thailand's public insurance schemes.

China's national medicines regulator.

Administers medicine price controls in India.

Exceptional-circumstances pathway for funding treatment for an individual patient.

Evaluates pharmaceutical products and supports regulatory decisions in Malaysia.

China's national list of medicines covered by basic medical insurance.

Coordinates public-sector medical procurement in Saudi Arabia.

Dutch healthcare authority responsible for care-market regulation and billing structures such as medicine add-ons.

Switzerland's mandatory health-insurance benefit framework.

Recommends medicines for public reimbursement in Australia.

Intermediary that manages formularies, contracting and pharmacy benefits for payers.

Organizations that manage formularies, contracting and pharmacy benefits for payers.

Australia's national subsidized medicines program.

Conducts joint price negotiations for participating public drug plans.

HSE service that administers community medicine reimbursement schemes and claims.

Decides which medicines are publicly funded in New Zealand and under what conditions.

The Philippines' national health-insurance corporation.

Minimum benefits that South African medical schemes must cover for specified conditions and treatment standards.

Japan's scientific review agency for medicines and devices.

A maximum sale price set under Colombian direct price control.

National formulary guiding public-sector medicine selection and procurement in the Philippines.

Provides independent clinical advice to Pharmac.

Egyptian public route funding approved treatment for eligible patients at state expense.

A measure combining length and quality of life.

Coordinates therapeutic-positioning evaluations in Spain.

A structured plan for identifying, characterizing and minimizing medicine safety risks.

A contract that shares financial or outcome uncertainty between payer and manufacturer.

South Africa's national medicines and health-products regulator.

List of medicines subsidized for eligible patients in Singapore's public healthcare sector.

South Africa's regulated private-sector medicine price before permitted dispensing or logistics fees.

Saudi Arabia's medicines regulator and pricing authority.

Türkiye's national social insurer and reimbursement decision-maker.

Portugal's national health-technology assessment system linking appraisal, price and financing decisions.

The exhaustive positive list for routine ambulatory reimbursement under Swiss mandatory health insurance.

French rating of a medicine's absolute clinical benefit.

Portugal's tax-funded national health service.

A confidential Australian pricing arrangement that can separate the effective price from the published PBS price.

Provides central purchasing, digital and shared services for the Portuguese health system.

Evidence-based treatment guidance linked to public-sector essential-medicine selection.

Czech authority for medicine regulation and administrative price/reimbursement proceedings.

Brazil's tax-funded public health system.

Australia's medicines and medical-devices regulator.

Thailand's medicines and health-products regulator.

Türkiye's medicines regulator and pricing authority.

Swedish authority making binding outpatient medicine price and subsidy decisions and selected health-economic assessments.

Swiss therapeutic price comparison against reimbursed alternatives in the same indication.

Access to needed health services without financial hardship.

Egypt's strategic purchaser for the phased universal health-insurance system.

Egypt's phased national universal health-insurance system.

The United Kingdom of Great Britain and Northern Ireland; health-system implementation is devolved across its nations.

Coordinates decisions across French statutory health-insurance funds.

Colombian list/mechanism for specified medically necessary uses outside the INVIMA-approved label.

Centralises public procurement of medicines and medical supplies for Egyptian governmental entities.

Prospective per-capita resource used to finance the Colombian health benefit plan.

Poland's national medicines registration authority.

Czech designation and temporary reimbursement route for a highly innovative medicinal product.

Administers Vietnam's social health-insurance payment and claims functions.

Dutch ministry that decides GVS inclusion and can place or release expensive specialist medicines from the sluis.

Scientific advisory body supporting Zorginstituut assessments.

Dutch law that sets maximum medicine prices; the ceiling is distinct from GVS reimbursement and negotiated net cost.

The effectiveness, appropriateness and economic-efficiency criteria for Swiss statutory coverage.